SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 5) *

Vanda Pharmaceuticals Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
921659108
(CUSIP Number)
December 31, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
(Page 1 of 12 Pages)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
2.	Deerfield Mgmt, L.P.	RIATE BOX IF A MEMBER OF A GROUP*	(a) 🗆	
۷.	CHECK THE APPROP	RIATE BOX IF A MEMBER OF A GROUP	(a) ∟ (b) ⊠	
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLA	ACE OF ORGANIZATION		
	Delaware			
	5.	SOLE VOTING POWER		
NUMBER OF		0		
SHARES	6.	SHARED VOTING POWER		
BENEFICIALLY OWNED BY				
EACH	7.	0 SOLE DISPOSITIVE POWER		
REPORTING PERSON	,.	SOLL BISTOSTITY LTOWER		
WITH		0		
	8.	SHARED DISPOSITIVE POWER		
		0		
9.	AGGREGATE AMOUN	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0			
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	0.00%			
12.	TYPE OF REPORTING	PERSON*		
	PN			

1.	NAME OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	Deerfield Management	Company, L.P.		
2.	CHECK THE APPROP	RIATE BOX IF A MEMBER OF A GROUP*	(a) 🗆	
			(b) ⊠	
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLA	ACE OF ORGANIZATION		
	Delaware 5.	SOLE VOTING POWER		
	J.	SOLE VOTING FOWER		
NUMBER OF		0		
SHARES BENEFICIALLY	6.	SHARED VOTING POWER		
OWNED BY		0		
EACH REPORTING	7.	SOLE DISPOSITIVE POWER		
PERSON		0		
WITH	8.	SHARED DISPOSITIVE POWER		
9.	ACCRECATE AMOU	0 NT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9.	AGGREGALE AMOU	NI BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0			
10.	0. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	0.00%			
12.	TYPE OF REPORTING	G PERSON*		
	PN			
	LIN			

			ruge	
1.	NAME OF REPORTIN I.R.S. IDENTIFICATIO	G PERSONS IN NO. OF ABOVE PERSONS (ENTITIES ONLY)		
	Deerfield Partners, L.P.			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*		(a) (b)	
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
	5.	SOLE VOTING POWER		
NUMBER OF		0		
SHARES	6.	SHARED VOTING POWER		
BENEFICIALLY OWNED BY		0		
EACH REPORTING	7.	SOLE DISPOSITIVE POWER		
PERSON		0		
WITH	8.	SHARED DISPOSITIVE POWER		
9.	AGGREGATE AMOUN	0 NT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
3.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING LEAGUN			
10	0	ACCRECATE AMOUNT IN DOMASO, EVOLVIDES CERTAIN SHARES*		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	0.00%			
12.	TYPE OF REPORTING	FPERSON*		
	PN			

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	Deerfield Special Situat			
2.	CHECK THE APPROP	RIATE BOX IF A MEMBER OF A GROUP*	(a) □ (b) ⊠	
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLA	ACE OF ORGANIZATION		
	Delaware			
	5.	SOLE VOTING POWER		
NUMBER OF		0		
SHARES BENEFICIALLY	6.	SHARED VOTING POWER		
OWNED BY		0		
EACH REPORTING	7.	SOLE DISPOSITIVE POWER		
PERSON		0		
WITH	8.	SHARED DISPOSITIVE POWER		
		0		
9.	AGGREGATE AMOUN	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0			
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	0.00%			
12.	TYPE OF REPORTING	G PERSON*		
	PN			

1.	NAME OF REPORTIN			
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	Deerfield International			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PL.	ACE OF ORGANIZATION		
	British Virgin Islands			
	5.	SOLE VOTING POWER		
NUMBER OF		0		
SHARES	6.	SHARED VOTING POWER		
BENEFICIALLY OWNED BY		0		
EACH REPORTING	7.	SOLE DISPOSITIVE POWER		
PERSON		0		
WITH	8.	SHARED DISPOSITIVE POWER		
		0		
9.	AGGREGATE AMOU	I ^o NT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0			
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			
		· ·		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	0.00%			
12.	TYPE OF REPORTING	G PERSON*		
	PN			

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	James E. Flynn			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b)			
			(0) 🗠	
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLA	ICE OF ORGANIZATION		
	United States			
	5.	SOLE VOTING POWER		
NUMBER OF		0		
SHARES BENEFICIALLY	6.	SHARED VOTING POWER		
OWNED BY		0		
EACH REPORTING	7.	SOLE DISPOSITIVE POWER		
PERSON WITH		0		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	8.	SHARED DISPOSITIVE POWER		
		0		
9.	AGGREGATE AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0			
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	0.00%			
12.	TYPE OF REPORTING	PERSON*		
	IN			

CUSIP No.	921659108	13G	Page 8 of 12
Item 1(a).	Name of Issuer:		
	Vanda Pharmaceutical	s Inc.	
Item 1(b).	Address of Issuer's Pri	ncipal Executive Offices:	
	2200 Pennsylvania Av Suite 300E	enue, N.W.	
	Washington, D.C. 200	37	
Item 2(a).	Name of Person Filing		
	James E. Flynn, Deerf and Deerfield Internati	eld Mgmt, L.P., Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P., Deonal Master Fund, L.P.	eerfield Management Company, L.P.
Item 2(b).	Address of Principal B	usiness Office, or if None, Residence:	
		eld Mgmt, L.P., Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P., Deonal Master Fund, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017	eerfield Management Company, L.P.
Item 2(c).	Citizenship:		
	Deerfield Mgmt, L.P., limited partnerships;	Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Speci-	al Situations Fund, L.P Delaware
	Deerfield International	Master Fund, L.P British Virgin Islands limited partnerships;	
	James E. Flynn – Unit	ed States citizen	
Item 2(d).	Title of Class of Secur	ties:	
	Common Stock		
Item 2(e).	CUSIP Number:		
	921659108		
Item 3.	If This Statement is Fi	ed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing	is a:
(a)	☐ Broker or dealer	registered under Section 15 of the Exchange Act.	
(b)	☐ Bank as defined	in Section 3(a)(6) of the Exchange Act.	
(c)	☐ Insurance comp	any as defined in Section 3(a)(19) of the Exchange Act.	
(d)	☐ Investment com	pany registered under Section 8 of the Investment Company Act.	
(e)	☐ An investment a	dviser in accordance with Rule 13d-1(b)(1)(ii)(E);	
(f)	☐ An employee be	nefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);	

^{**}See footnotes on cover pages which are incorporated by reference herein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following \boxtimes .

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD INTERNATIONAL MASTER FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Date: February 14, 2018

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney (1).

(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.

Exhibit A

Joint Filing Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Vanda Pharmaceuticals Inc. shall be filed on behalf of the undersigned.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: <u>/s/ Jonathan Isler</u>

Jonathan Isler, Attorney-In-Fact

DEERFIELD INTERNATIONAL MASTER FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Exhibit B

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a	"group" with one another for purposes of
Section 13(d)(3) of the Securities Exchange Act of 1934.	